Related Experiment Videos
Disability in young patients suffering from primary headaches
1Headache Centre, National Neurological Institute C Besta, Via Celoria 11, I-20123 Milan, Italy. liciagrazzi@mac.com
Summary
Researchers adapted the MIDAS Questionnaire for children and adolescents to measure headache disability. This new version proved reliable and sensitive to treatment, offering a valuable tool for pediatric headache management.
Area of Science:
- Neurology
- Pediatrics
- Epidemiology
Background:
- Primary headaches significantly impact children and adolescents, with prevalence increasing sharply by age 15.
- Standardized tools are needed to measure headache-related disability in young populations.
- The original MIDAS Questionnaire (Migraine-Specific Quality of Life) was validated for adults but not specifically for pediatric use.
Purpose of the Study:
- To develop and validate a new version of the MIDAS Questionnaire tailored for young patients with various headache types.
- To assess the reliability and test-retest reliability of the adapted pediatric MIDAS Questionnaire.
- To evaluate the sensitivity of the new instrument to treatment interventions in children and adolescents.
Main Methods:
- Adaptation of the original MIDAS Questionnaire for a pediatric population.
- Reliability testing, including internal consistency and test-retest reliability.
- Sensitivity analysis by assessing changes in scores following treatment.
Main Results:
- A new version of the MIDAS Questionnaire specifically designed for young patients was successfully produced.
- The adapted questionnaire demonstrated good reliability and was sensitive to treatment interventions.
- This indicates the new instrument is suitable for assessing headache-related disability in children and adolescents.
Conclusions:
- The adapted MIDAS Questionnaire is a reliable and valid instrument for assessing headache-related disability in children and adolescents.
- This tool can aid clinicians in managing pediatric headache disorders.
- Further research should explore its use across diverse pediatric headache populations and geographical settings.